



# SNO Digest

Weekly news from  
the Society for Neuro-Oncology

## 2022 SNO Annual Meeting - Call for Abstracts

The Call for Abstracts for the 2022 SNO Annual Meeting is now open! The abstract deadline is Wednesday, June 1, 2022, at 11:59pm EDT. **This deadline will not be extended.**

SNO is pleased to introduce three new submission categories for the 2022 Annual Meeting, including:

- Cancer Neuroscience
- Health Disparities and Equity
- Quality Improvement

For full information on submission categories, [click here](#). To submit an abstract, [click here](#).

## On-Demand Webinars



The SNO Pediatrics Special Interest Track would like to thank the physicians who have presented and shared their expertise and the patients and families who allowed their cases to be shared to improve our education in the pediatric neuro-oncology community. The latest broadcast of the Pediatric Tumor Board Series is now available on demand [here](#).



If you did not have the opportunity to catch the webinar, "The Neural Regulation of Cancer," jointly sponsored by the World Federation of Neurology and the Society of Neuro-Oncology, it is available on-demand [here](#).


## Clinical Trials

### Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

Immunotherapy has revolutionized cancer treatment for multiple tumor types, but immunotherapy faces multiple challenges in the case of glioblastoma. This NRG sponsored national phase II/III trial compares the standard of care treatment with radiation therapy and temozolomide to radiation therapy in combination with immunotherapy with ipilimumab and nivolumab in treating patients with newly diagnosed MGMT unmethylated glioblastoma.

[Read more here.](#)

# From The Journals



## Short-term outcomes associated with temozolomide or PCV chemotherapy for 1p/19q-codeleted WHO grade 3 oligodendrogliomas: A national evaluation

The optimal chemotherapy regimen between temozolomide and procarbazine, lomustine, and vincristine (PCV) remains uncertain for WHO grade 3 oligodendroglioma (Olig3) patients. We therefore investigated this question using national data.

[Click to read the full article.](#)

## SNO Public Policy

SNO members are encouraged to register to join the National Brain Tumor Society and their fellow advocates for Head to the Hill on May 2-3, 2022. All interested participants must register individually. Head to the Hill is our annual advocacy event where individuals help policymakers better understand the urgent, unmet needs of the brain tumor community. There are **both in-person and virtual participation** options this year. To register for this exciting event, [click here](#). If you would like to attend in person but require a scholarship to cover your hotel costs, [you can apply for one here](#).

## SNO Career Center




### This Week's Featured Listing

University of Arizona Cancer Center is actively recruiting an experienced, board-certified Neuro-Oncologist. The hired physician will have the opportunity to develop a specialty clinical practice in academic Neuro-Oncology, educate residents and medical students, and conduct innovative clinical and/or basic science research.

[Click here to apply or see other postings!](#)

## Upcoming SNO and SNO Affiliated Events



### 2022 SNO Annual Meeting and Education Day - Call for Abstracts

Abstract deadline - June 1, 2022

For information on the submission categories and requirements,

please [click here](#).

To submit an abstract, please [click here](#).




### The 20th International Symposium of Pediatric Neuro-Oncology (ISPNO 2022)

June 12-15, 2022, in Hamburg

[Register Here](#)

For information about travel grants for LMIC countries, please [click here](#).



## 2022 SNO Introduction to Clinical Trial Design and Protocol Development Workshop

August 11, 2022

Application deadline - April 15, 2022

[Apply Here](#)

## 2nd Annual Conference on Clinical Trials and Brain Metastases

August 12-13, 2022

Call for Abstracts - Deadline: April 18,  
2022

[Submit Your Abstract](#)

## SNO Membership

Want access to SNO's official journal, *Neuro-Oncology*, bi-monthly publication, *Neuro-Oncology Practice*, and complimentary online subscription to *Neuro-Oncology Advances*? **Now is the time to renew your membership or join the Society.** Click [here](#) today to get started.

*SNO Digest is written and distributed by the Society for Neuro-Oncology. All content, including images, may not be reproduced unless permission is granted from SNO. If you would like to contribute to upcoming issues of the SNO Digest or if you have questions, please contact us at [snodigest@soc-neuro-onc.org](mailto:snodigest@soc-neuro-onc.org).*



See you in  
**Tampa Bay!**

27<sup>th</sup> Annual Meeting of the Society for Neuro-Oncology, November 16-20, 2022

Society for Neuro-Oncology | [Website](#)  
[Subscribe to the SNO Digest](#)



Society for Neuro-Oncology | PO 273296, Houston, TX 77277

[Unsubscribe megan@soc-neuro-onc.org](mailto:megan@soc-neuro-onc.org)

[Update Profile](#) | [About Constant Contact](#)

Sent bysnodigest@soc-neuro-onc.org in collaboration  
with



Try email marketing for free today!